DrugPatentWatch Database Preview
Shire Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for SHIRE, and what generic alternatives to SHIRE drugs are available?
SHIRE has thirty-eight approved drugs.
There are twenty-eight US patents protecting SHIRE drugs.
There are two hundred and eighty-three patent family members on SHIRE drugs in forty-two countries and sixteen supplementary protection certificates in eleven countries.
Summary for Shire
| International Patents: | 283 |
| US Patents: | 28 |
| Tradenames: | 34 |
| Ingredients: | 25 |
| NDAs: | 38 |
| Patent Litigation for Shire: | See patent lawsuits for Shire |
| PTAB Cases with Shire as patent owner: | See PTAB cases with Shire as patent owner |
Drugs and US Patents for Shire
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-005 | Jan 28, 2017 | RX | Yes | No | 7,678,771 | Start Trial | Y | Start Trial | |||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-005 | Dec 10, 2007 | RX | Yes | No | 7,687,466 | Start Trial | Y | Start Trial | |||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-004 | Jan 28, 2017 | RX | Yes | No | 7,713,936 | Start Trial | Start Trial | ||||
| Shire Dev Llc | VYVANSE | lisdexamfetamine dimesylate | TABLET, CHEWABLE;ORAL | 208510-002 | Jan 28, 2017 | RX | Yes | No | 7,105,486 | Start Trial | Start Trial | ||||
| Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-003 | Feb 23, 2007 | RX | Yes | Yes | 7,678,771 | Start Trial | Y | Start Trial | |||
| Shire | ADDERALL XR 30 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021303-003 | Oct 11, 2001 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Shire
Paragraph IV (Patent) Challenges for SHIRE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
| ➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
| ➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
| ➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
| ➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
| ➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
| ➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
International Patents for Shire Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1720059 | Start Trial |
| Mexico | 2007012507 | Start Trial |
| European Patent Office | 2645995 | Start Trial |
| Australia | 2001286599 | Start Trial |
| Germany | 602004025950 | Start Trial |
| Mexico | PA06002257 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shire Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0370453 | C300359 | Netherlands | Start Trial | PRODUCT NAME: ICATIBANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, BIJ VOORKEUR ICATIBANTACETAAT; REGISTRATION NO/DATE: EU/1/048/461/001 20080711 |
| 0370453 | SPC/GB09/002 | United Kingdom | Start Trial | PRODUCT NAME: ICATIBANT, OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF, INCLUDING ICATIBANT ACETATE; REGISTERED: UK EU/1/08/461/001 20080711 |
| 1613296 | CR 2015 00042 | Denmark | Start Trial | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| 1644019 | SPC/GB13/052 | United Kingdom | Start Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201 |
| 1644019 | C01644019/01 | Switzerland | Start Trial | PRODUCT NAME: LISDEXAMPHETAMIN; REGISTRATION NO/DATE: SWISSMEDIC 63023 27.03.2014 |
| 1644019 | CA 2013 00043 | Denmark | Start Trial | PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
